Loading...
XNAS
GALT
Market cap369mUSD
Dec 05, Last price  
5.74USD
1D
-8.89%
1Q
24.78%
Jan 2017
485.71%
IPO
-52.17%
Name

Galectin Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:GALT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.59%
Rev. gr., 5y
%
Revenues
0k
Net income
-47m
L+14.56%
-6,544,000-3,193,000-9,433,000-3,151,000-7,462,000-5,629,000-10,915,000-9,675,000-12,088,000-15,788,000-20,027,000-21,436,000-16,235,000-13,900,000-13,381,000-23,516,000-30,975,000-39,200,000-41,066,000-47,047,000
CFO
-42m
L+26.70%
-6,127,000-6,757,000-5,483,000-4,665,000-3,887,000-3,102,000-5,676,000-7,500,000-7,484,000-12,426,000-16,983,000-16,409,000-15,892,000-10,179,000-10,848,000-20,601,000-24,308,000-31,056,000-32,965,000-41,767,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
URL
https://galectintherapeutics.com/
IPO date
Sep 04, 2002
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT